menu
    • menu
    [{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Bausch Health","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Acquisition","leadProduct":"Risuteganib","moa":"Integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Allegro Ophthalmics \/ Bausch Health","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Ophthalmics \/ Bausch Health"},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Bausch Health","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Acquisition","leadProduct":"Risuteganib","moa":"Integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Allegro Ophthalmics \/ Bausch Health","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Ophthalmics \/ Bausch Health"},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Risuteganib","moa":"Integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Allegro Ophthalmics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Ophthalmics \/ Inapplicable"},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Risuteganib","moa":"Integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Allegro Ophthalmics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Ophthalmics \/ Inapplicable"},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Risuteganib","moa":"Integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Allegro Ophthalmics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Ophthalmics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Allegro Ophthalmics

    Menu

    Allegro Ophthalmics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Allegro Ophthalmics

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Allegro Ophthalmics

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Risuteganib

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allegro Ophthalmics Receives FDA Agreement Under Special Protocol Assessment (SPA) for Phase 2b/3 Clinical Tri...

                            Details : Luminate® (risuteganib) is a novel anti-integrin peptide that targets the multiple integrin heterodimers involved in the pathophysiology of dry AMD, it is being investigated for the treatment of intermediate, non-exudative age-related macular degenerati...

                            Product Name : Luminate

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            December 04, 2023

                            Lead Product(s) : Risuteganib

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Allegro Ophthalmics

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Allegro Ophthalmics

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Risuteganib

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allegro Ophthalmics Announces Presentation of Key Data Surrounding Dry AMD Pipeline Candidates, Treatment Cons...

                            Details : Pre-clinical data suggest that Luminate (risuteganib), Allegro’s lead investigational compound in retina, may simultaneously act on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases, such as dry AMD.

                            Product Name : Luminate

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            October 02, 2023

                            Lead Product(s) : Risuteganib

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Allegro Ophthalmics

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Allegro Ophthalmics

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Risuteganib

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            U.S. Phase 2 Study Published in OSLI Retina Highlights the Safety and Efficacy of Risuteganib in Dry Age-Relat...

                            Details : These clinical data suggest that risuteganib can reverse vision loss and restore functional vision in patients with intermediate dry AMD with treatment at a 12-week interval.

                            Product Name : Luminate

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            March 08, 2021

                            Lead Product(s) : Risuteganib

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Allegro Ophthalmics

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Allegro Ophthalmics

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Risuteganib

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Bausch Health

                            Deal Size : $50.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Bausch Health To Acquire Option To Purchase All Ophthalmology Assets Of Allegro Ophthalmics

                            Details : Bausch Health, has entered into an agreement to acquire an option to purchase all ophthalmology assets of Allegro, including global rights for risuteganib (Luminate). Allegro include ALG-1007, a topical integrin regulator under investigation for treatmen...

                            Product Name : Luminate

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            September 21, 2020

                            Lead Product(s) : Risuteganib

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Bausch Health

                            Deal Size : $50.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Allegro Ophthalmics

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Allegro Ophthalmics

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Risuteganib

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Bausch Health

                            Deal Size : $50.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Bausch Health To Acquire Option To Purchase All Ophthalmology Assets Of Allegro Ophthalmics

                            Details : The agreement provides Bausch with global rights for risuteganib, Allegro's lead investigational compound in retina, including Other ophthalmology assets such as Allegro's ALG-1007, a topical integrin regulator under investigation for the treatment of dr...

                            Product Name : Luminate

                            Product Type : Peptide

                            Upfront Cash : $10.0 million

                            September 21, 2020

                            Lead Product(s) : Risuteganib

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Bausch Health

                            Deal Size : $50.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth